Samantha Du, Zai Lab CEO (Zai Lab)

Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el

Look­ing to cap­i­tal­ize on a bustling Chi­nese drug mar­ket, up­start biotechs like Saman­tha Du’s Zai Lab have made a killing in-li­cens­ing for­eign mol­e­cules as well as de­vel­op­ing their own home­grown as­sets. Now, with even more growth in mind, Zai Lab has of­fered up a healthy chunk of shares on the US mar­ket to fu­el its am­bi­tions.

Zai Lab will of­fer $750 mil­lion in US de­pos­i­to­ry shares as part of a ma­jor cash raise to keep dri­ving its in-li­cens­ing busi­ness en­gine as well as ad­vance its suite of clin­i­cal pro­grams, the Chi­nese biotech said this week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA